Topical 5% imiquimod for the therapy of actinic cheilitis
- 1 October 2002
- journal article
- Published by Elsevier in Journal of the American Academy of Dermatology
- Vol. 47 (4) , 497-501
- https://doi.org/10.1067/mjd.2002.126266
Abstract
No abstract availableKeywords
This publication has 16 references indexed in Scilit:
- Imiquimod 5% cream in the treatment of Bowen's diseaseJournal of the American Academy of Dermatology, 2001
- Bowen's Disease (Squamous Cell Carcinoma In Situ) in Immunosuppressed Patients Treated with Imiquimod 5% Cream and a COX Inhibitor, Sulindac: Potential Applications for This Combination of ImmunotherapyDermatologic Surgery, 2001
- The Imidazoquinolines, Imiquimod and R-848, Induce Functional, but Not Phenotypic, Maturation of Human Epidermal Langerhans' CellsClinical Immunology, 2000
- Imiquimod, a Topical Immune Response Modifier, Induces Migration of Langerhans Cells11The authors have declared a conflict of interest.Journal of Investigative Dermatology, 2000
- Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% creamJournal of the American Academy of Dermatology, 1999
- Modulation of TH1 and TH2 Cytokine Production with the Immune Response Modifiers, R-848 and ImiquimodCellular Immunology, 1999
- Cytokine Induction in Hairless Mouse and Rat Skin After Topical Application of the Immune Response Modifiers Imiquimod and S-28463Journal of Investigative Dermatology, 1998
- Interleukin-12: a proinflammatory cytokine with immunoregulatory functionsResearch in Immunology, 1995
- Clinical Advantage of the CO2Laser Superpulsed ModeThe Journal of Dermatologic Surgery and Oncology, 1994
- CRYOSTATIC CONGELATIONJournal of Nervous & Mental Disease, 1961